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Background. Bisphosphonates are well established in the management of 
cancer-induced skeletal complications. Recent studies suggest that 
bisphosphonates promote apoptosis of cancer cells as well as osteoclasts in 
bone metastatic sites. In the present study, to determine the direct effects of 
bisphosphonate on prostate cancer, we examined the effects of minodronate 
on prostatic cancer cell growth and the expression of apoptosis related 
proteins and osteoclastogenic factors. 
Methods. The amino-bisphosphonate minodronate was added to PC-3, 
DU145 and LN-CaP. Cell proliferation, apoptosis and expression of bcl-2, 
bax, PARP, caspase-3, RANKL, OPG, MMP-2 and PTHrP was assessed. 
Results. The cell proliferation of LN-CaP, DU145 and PC-3 cells were 
inhibited by minodronate. DNA fragmentation and TUNEL positive nuclei 
were observed in minodronate treated PC-3 cells. Bcl-2/bax ratio, expression 
of poly (ADP)-ribose polymerase (PARP), and caspase-3 were regulated by 
minodronate in DU145 and PC-3 cells. Furthermore, decreased expression 
of RANKL, MMP-2 and PTHrP mRNA and protein were observed in PC-3 
cells.  
Conclusions. Our results suggest that bisphosphonate not only promotes 
apoptosis directly but also regulates expression of genes associated with 
osteolysis in prostatic cancer cells. 
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Introduction 
Early staged prostate cancer can be cured completely because of recent 
development of hormone, radiation therapy, or surgical operation. However, 
only hormone therapies are available for advanced prostate cancer (1) but 
those effects are limited because character of prostate cancer with hormone 
therapies changes to androgen-independent phenotype in several years (2-4). 
About 80% of metastatic prostatic cancer occurs in multiple bones (pelvis or 
vertebra, femur, etc) (5). Management of bone metastases which cause 
pathological fracture, nerve paralysis and movement restrictions is very 
important for improvement and maintenance of patient's quality of life and 
prognosis (6-8). However, the effective treatment for hormone refractory 
prostate cancer with bone metastasis has not been established yet.  
Bisphosphonates are analogues of endogeneous pyrophosphate in which a 
carbon atom replaces the central atom of oxygen. In vivo, bisphosphonate 
binds strongly to hydroxyapatite on the bone surface and are preferentially 
delivered sites of increased bone formation or resorption. They are potent 
inhibitors of osteoclast-mediated bone resorption and are effective in 
lowering serum calcium concentration. Bisphosphonates have direct effects 
on osteoclasts, inducing apoptosis through mevalonate pathway and 
preventing the isoprenylation of small GTP-binding proteins such as Ras 
and Rho. These effects results in inhibition of bone absorption (9-11). 
Recently, bisphosphonates have been shown to reduce bone pain, improve 
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quality of life, and to delay skeletal event in patients with breast cancer or 
multiple myeloma (12,13). In addition, bisphosphonates have been shown to 
exhibit direct anti-tumor effects in some kinds of cancer cells (14-16). In 
clinical study of prostate cancer, bisphosphonate treatment of painful 
osseous metastases due to hormone refractory prostate cancer results in a 
significant pain decrease and a significant decrease in the daily 
consumption of analgesics in 75% of patients (17). However, mechanism of 
these in vivo effects of bisphosphonete has not been fully elucidated yet.  
In this study, in order to clarify the mechanisms for therapeutic effects of 
bisphosphonates on hormone refractory prostate cancer, we evaluated the 
effects of bisphosphonate on the regulation of proliferation and apoptosis 
and cytokine or growth factor expression in prostate cancer cell lines using 










Materials and methods 
Reagents. 
Minodronate (MIN, also known as YM-529) and incadronate (INC, also 
known as YM175) were gifted from Yamanouchi (Tokyo, Japan). 
Minodronate was dissolved in 1N NaOH then the pH adjusted to 7.4. 
Bisphosphonates were prepared in phosphate buffered saline and then 
diluted prior to addition to cell cultures.  
 
Cell line and cell culture. 
The human prostatic cancer cell line PC-3, DU145 and LNCaP were 
maintained in RPMI or DMEM medium supplemented with antibiotics and 
10% fatal bovine serum (FBS). Cells were passaged by trypsinization and 
cultured at 37℃ in 5% CO2. All of the medium and reagents were from 
Sigma-aldrich, Missouri, USA. 
 
Cell proliferation assay  
Prostate cancer cell line PC-3, DU145 and LNCaP were plated at a density 
of 5×105 cells onto 6 well plates with DMEM or RPMI-10% FBS and allowed 
to adhere and proliferate for 24 h. Then cells were incubated with fresh 
medium containing increasing concentrations of minodonate or incadronate 
for 72 h, or cells were incubated with fresh media containing 10 μM of 
YM529 for 24, 48, 72 h, respectively. In each experiment, cells were 
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harvested and cell number was determined using a haemocytometer. 
 
Detection of Apoptosis using DNA fragmentation assay. 
5×104 PC-3 cells were plated onto 6 wells plates, allowed to adhere overnight 
and treated with minodronate at the indicated concentrations, or 
estramustine phosphate (20 μM) as positive control for 24 h. Cells were 
harvested and DNA was extracted and 10 μg of DNA samples were 
electrophoresed on an 1.5 % agarose gel using Apoptosis ladder detection kit 
(WAKO, Osaka, Japan). After electrophoresis, staining in SYBRTM Green I 
Working Solution was performed. To visualize bands, an UV 
transilluminator of wave length 254 nm with Yellow Gelatin Filter was 
used. 
 
Detection of Apoptosis using TUNEL assay. 
After 5×104 PC-3 and DU145 cells were plated, cells were treated with 10 
μM minodronate for 24 h. A TUNEL (terminal deoxynucleotidyl 
transferase-mediated dUTP-biotin nick end labeling) technique was 
performed to detect apoptotic cells using In situ Apoptosis Detection Kit 
(TAKARA BIO INC, Shiga, Japan) according to the manufacturer 
instruction. Fluorescene microscopy was used to confirm the existence of 
positively stained cells.  
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Measurement of activity of caspase-3. 
After 3×105 PC-3 and DU145 cells were plated onto 6 wells plates, and cells 
were treated with 30 μM minodronate in the absence or presence of 20 μM 
of broad caspase-3 inhibitor: Z-VAD-FMK. The caspase-3 specific activity in 
PC-3 and DU145 was determined using CaspACETM ASSAY System, 
Colorimetric (Promega, Wisconsin, USA) according to manufacturer 
instructions. Then, cells were harvested and cell number was determined 
using a haemocytometer. 
 
RT-PCR. 
Total RNA was extracted using ISOGEN (Nippon Gene, Tokyo, Japan). To 
make complementary DNA from 1 μg total RNA, reverse transcription was 
performed using ThermoScriptTMRT (Invitrogen, California, USA). RT-PCR 
was performed using TaKaRa Ex TaqTM Hot Start Version (TAKARA BIO 
INC, Shiga, Japan) and the following primers: human/mouse TRANCE PCR 
Primer PairTM (R&D systems, Minneapolis, USA) for RANKL, human/mouse 
OPG PCR Primer PairTM (R&D systems) for OPG, human/mouse MMP-2 
PCR Primer PairTM (R&D systems) for MMP-2. RT-PCR condition for 
RANKL was 94℃ for 4 min followed by 35 cycles of 94℃ for 45s/56.5℃ for 
45s/72℃ for 45s, for OPG 94℃ for 4 min followed by 30 cycles of 94℃ for 
45s/55.5℃ for 45s/72℃ for 45s and for MMP-2 94℃ for 4 min followed by 
33 cycles of 94℃ for 30s/55℃ for 30s/72℃ for 30s, for PTHrP 94℃ for 4 
 7
min followed by 20 cycles of 94℃  for 30s/55℃  for 30s/72℃  for 30s 
respectively. Rt-PCR products were electrophoresed on an 1.5% agarose gel 
and visualized by ethidium bromide staining under UV light. 
 
OPG protein measurement. 
After 5×104 PC-3 cells were plated onto 6 wells plates, cells were treated 
with minodronate for 24 h. Conditioned medium was harvested and 
centrifuged to remove debris. Samples were stored at –80℃ until used. 
OPG protein secretion was determined using Osteoprotegerin ELISA kit 
(BIOMEDICA, Wien, AUSTRIA) according to manufacturer instruction. 
 
Western Blotting 
After 5×105 PC-3 cells were plated, cells were treated with minodronate for 
24 h. Then, cells were lysed with lysis buffer composed of 50 mM Tris-HCl, 
150 mM Sodium chloride (NaCl) pH8.0, 0.1% Triton X-100, 0.01 mg/ml 
aporotinin and 0.05 mg/ml phenylmethylsulphonyl fluoride. Protein was 
quantified by methods of bradford and equal amount of protein were loaded 
and electrophoresed on a 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresismini gel. Proteins were transferred to PVDF membrane and 
preblocked with casein PBS and 0.05% Tween-20 for 1 h at room 
temperature. Membranes were incubated with mouse monoclonal antibody 
against bcl-2 (Santa Cruz, California, USA), PARP (Santa Cruz) and rabbit 
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monoclonal antibody against bax (Santa Cruz), MMP-2 (Santa Cruz) and 
RANKL (Santa Cruz) and goat monoclonal antibody against PTHrP (Santa 
Cruz). Horse radish peroxidase-conjugrated secondary antibody against 
anti-mouse or rabbit or goat monoclonal antibody was used and protein 
bands were visualised with enhanced chemiluminescence reagent.  
 
Statistics  
Experiments were performed in triplicate unless otherwise stated. All 















Cell proliferation study. 
To evaluate the effect of bisphoshonates on proliferation of prostate cancer, 
we examined the number of minodronate treated prostatic cancer cells. 
Exposure of 0-100 μM minodronate for 72 h significantly inhibited the cell 
proliferation of PC-3, DU145 and LNCaP in a dose dependent manner. 
Compared with incadronate which is ordinal third generation 
bisphosphonate, minodronate significantly showed more potent effect than 
incadronate in inhibition of growth of prostate cancer cells (Fig. 1A). To 
evaluate whether effect of minodronate is time dependent, we examined the 
number of minodronate treated prostatic cancer cells every 24 h. Exposure 
of 10 μM minodronate significantly inhibited proliferation of PC-3, DU145 
and LNCaP cells in a time dependent manner, compared to control (Fig. 1B).  
IC50 value for incadronate in LNCaP, DU145 and PC-3 was 31.6 μM, 17.0 
μM and 37.1 μM, whereas that for minordinate was 2.62 μM, 0.92 μM and 
18.8 μM, respectively (Table.1).  
 
Detection of apoptosis. 
To investigate whether minodronate induce apoptosis in inhibition of cell 
growth of prostate cancer, we performed DNA fragmentation assay and 
TUNEL assay. 10-100 μM of minodronate exposure for 24 h induced DNA 
fragmentation in PC-3 cells in a dose dependent manner (Fig. 2A). In 
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TUNEL assay, apoptotic nuclei were observed in PC-3 cells with 10 μM of 
minodronate treatment (Fig.2B). In DU145 cells, the same phenomenon was 
observed (date not shown). These results suggest that minodronate directly 
caused apoptosis in PC-3 cells at the concentration of at least 10 μM of 
minodronate.  
 
Effects of bisphosphonate on expression of bcl-2 and bax. 
A number of genes and proteins are implicated in the regulation of apoptosis. 
It has been demonstrated that the bcl-2 gene product confers resistance to 
apoptosis induced by a numbers of stimuli, whilst its homologue, bax, 
promotes apoptosis (18,19). In order to investigate mechanism of apoptosis 
by bisphosphonate in prostate cancer cells, expression of bcl-2 and bax were 
evaluated by western blotting. Decreased expression of bcl-2 was observed 
at the concentration of 30 μM of minodronate (Fig.3A). In contrast, there 
was no remarkable regulation in expression of Bax (Fig.3B). Yin et al. 
reported that the susceptibility of a cell to undergo apoptosis depends in 
part on the ratio of bcl-2 to bax (18). When bcl2/bax expression ratio was 
calculated from results of western blotting, minodronate treatment reduced 
the ratio in PC-3 and DU145 in a dose dependent manner (Fig.3C).  
 
Effects of minodronate on expression of caspase-3 and poly (ADP)-ribose 
polymerase (PARP). 
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Caspase-3 is the most prevalent caspase and it is responsible for the 
majority of apoptotic effects. To investigate the effect of minodronate on 
caspase-3 activity, we assessed the activity of caspase-3 in PC-3 and DU145. 
Compared to control, caspase-3 activity was significantly increased with 30 
μM of minordinate treatment for 24 h (Fig.4A). In contrast, treatment of 
minodronate with additional Z-VAD-FMK resulted in decreased caspase-3 
activity in PC-3 and DU145, compared with treatment of minodronate alone. 
In addition, when minodronate was added with Z-VAD-FMK, the number of 
the survived cell was partially recovered in PC-3 and DU145 (Fig.4B). These 
results suggest that effect of minodronate on apoptosis induction is mainly 
caspase-dependent. Another key feature of apoptosis is proteolytic cleavage 
of PARP as a consequence of activation of caspases. It has been suggested 
that PARP inhibits DNA fragmentation through ribosylation of DNA. 
Full-length active PARP is a 116 kDa molecule which is cleaved to 
fragments of 85 kDa and 30 kDa by the action of caspase-3 and related 
caspases (20). In order to determine the effect of minodronate on PARP 
activity, expression of full-length PARP in PC-3 and DU145 was examined 
by western blotting. Decreased expression of PARP was observed at the 
concentration of 30 μM of minodronate in both cell lines (Fig.5). This 
implies that decreased expression of PARP followed by caspase-3 activation 
cause DNA fragmentation. 
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Effect of minodronate on expression of growth factors and cytokines derived 
from prostatic cancer cells. 
Various cancer cells secrete a number of growth factors and cytokines that 
stimulate osteoclast which cause bone resorption. It has been suggested that 
prostate cancer cells also release various kinds of growth factors and 
cytokine, which promote osteoclastgenesis in bone tissue (21). To determine 
the effect of bisphosphonate on secretion of promoter proteins for 
osteoclastgenesis, expression of RANKL and OPG was assessed by RT-PCR, 
ELISA or western blotting and expression of MMP-2 and PTHrP were 
examined by RT-PCR and western blotting. 
In RT-PCR, addition of minodronate to PC-3 cells for 24 h decreased RANKL 
mRNA level in a dose dependent manner. In western blotting, expression of 
RANKL also decreased in a dose dependent manner (Fig.6A). In contrast, 
mRNA and protein expression of OPG was not regulated with minodronate 
treatment in PCR or ELISA (Fig.6B). 
Next, we examined MMP-2 expression in minodronate treated PC-3. In 
RT-PCR, mRNA expression of MMP-2 decreased in a dose dependent 
manner with minodronate treatment. In addition, protein expression of 
MMP-2 also decreased in a dose dependent manner in minodronate treated 
PC-3 cells (Fig.6C). 
Expression of PTHrP protein was also decreased in minodronate treated 
PC-3. However, mRNA expression of PTHrP was not altered with 
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It has been suggested that bisphosphonate indirectly inhibited growth of 
cancer cells by inhibition of bone absorption mediating through inducing 
apoptosis of osteoclast (15,22). However, there is increasing evidence that 
bisphosphonates may have direct inhibitory effects on cancer cells. In breast 
cancer, Senaratne et al. demonstrated that pamidronate inhibited cell 
proliferation of MDA-MB-231 by inducing proteolysis of PARP through 
bcl-2/bax ratio regulation (14). In prostate cancer, Lee et al. demonstrated 
that pamidronate inhibited cell proliferation of PC-3 and DU145 and 
LN-CaP in vitro (23). Moreover, Virtanen et al. reported that alendronate 
induced apoptosis and prevented invasion of prostate cancer cells by 
inhibiting mevalonate pathway (24). In the present study, minodronate, 
which is a new bisphosphonate of the third generation significantly, 
decreased the number of prostate cancer cell in dose and time dependent 
manner, showing the direct effect in LNCaP, DU145 and PC-3. This is the 
same result with the previously reported by others. In addition, 
minodronate treatment induced DNA fragmentation in a dose dependent 
manner, and TUNEL assay showed the appearance of apoptotic nucleus in 
PC-3 with minodronate treatment. These findings suggest that 
bisphosphonates have direct effect on prostate cancer cells by inducing 
apoptosis. In recent study, Oades et al. demonstrated that 10 μM of 
zoledronate directly induced apoptosis in prostatic cancer cell lines (25). As 
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compared with IC50 value of incadronate, which is the conventional 
bisphosphonate of third generation, the IC50 of minodronate was 
significantly lower than of incadronate in each prostate cancer cell lines and 
this suggests that minodronate had more potent effect than incadronate.  
In the present study, we clearly demonstrated that minodronate decreased 
PARP activity following bcl-2/bax regulation and caspase-3 activation. These 
results suggest that direct effect of bisphosphonate on cancer cells might be 
caspase-3 dependent. However, in our study, addition of caspase inhibitor: 
Z-VAD-FMK to minodronate partially recovered cell survival rate compared 
with minodronate alone in PC-3 and DU145 cells.  This finding raises 
possibility that other caspases like caspase-8 or -9 also might been involved 
in the apoptosis signaling pathway induced by bisphosphonate since these 
caspase-3 family members are substrates for upstream caspases. As another 
mechanism of apoptosis induction by bisphosphonate, a recent study has 
suggested that amino-bisphosphonate inhibit farnesyl pyrophosphate 
synthase in the cholesterol biosynthetic pathway in osteoclasts (10). In 
study of macrophage like cell line J774, Benford et al. demonstrated that 
amino-bisphosphonates blocks mevalonate pathway of J774 in inducing 
apoptosis (11). Mevalonate pathway is a part of cholesterol biosynthesis 
pathway, which mediates isoprenylation of small GTP binding proteins such 
as Rac, Rho, Rab and Ras family. Oades et al. demonstrated that zoledronic 
acid impair membrane localization of isoprenylated Ras also in apoptotic 
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prostate cancer cells (25). However, it still remains unclear whether 
inhibited isoprenylation of small GTP binding proteins can regulate the 
expression of bcl-2/bax or activation of caspases.  
In the present study, we have found decreased expression of RANKL mRNA 
and protein but stable expression of OPG in PC-3 with minodronate 
treatment. This is the first report that demonstrated down-regulation of 
RANKL by bisphosphonate in prostate cancer although down-regulation of 
RANKL was shown in study of multiple myeloma (26). RANKL is a member 
of the TNF family, which is initially expressed by bone marrow stromal cells, 
osteoblasts and activated T cells (27). RANKL is mainly a 
membrane-anchored molecule. However, small fraction of RANKL is 
released through proteolytic cleavage cell surface as a soluble homotrimeric 
molecule and both kinds of RANKL promote osteoclast formation and 
activation by binding to RANK on the osteoclast precursor membrane (28). 
Prostate cancer is known to express membrane anchored and soluble 
RANKL (21,29). In contrast, OPG acts as a decoy receptor against RANKL 
and expression of OPG by osteoblasts under hormone regulation is thought 
to inhibit osteoclastgenesis by binding the differentiating factor (30). In 
immunohistochemical study, bone metastases of prostate cancer were 
consistently immunoreactive for both RANKL and OPG compared with 
non-osseous metastases or primary prostate cancer (31). In addition, it has 
been demonstrated that the induction of osteoclastgenesis is dependent 
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upon the relative abundance of RANKL compared with the level of OPG (32). 
Therefore, our data suggests that down regulation of RANKL with stable 
OPG levels from cancer cells with minodronate treatment might cause 
reduction of local osteoclast formation and activation in prostate cancer.  
Various cancer cells secrete matrix metalloproteinases (MMPs) and MMPs is 
essential factor for invasion and metastasis in cancer cells. MMPs have an 
important role also in bone remodeling. In study of mouse calvaria, Kusano 
et al. demonstrated that induction of MMP-2, -3, -9 and -13 by IL-1 and IL-6 
is closely linked to the respective bone-resorbing activity, suggesting that 
MMP-dependent degradation of bone matrix plays a key role in bone 
resorption (33). Prostate cancer secretes a large number of MMPs (34-38) 
and recently, Liao et al demonstrated that androgen stimulation increased 
expression of MMP-2 in prostate cancer (39). In the present study, we 
demonstrated that high concentration of minodronate inhibited mRNA and 
protein expression of MMP-2 in PC-3. In support for our observation, 
Stearns et al. demonstrated that decreased activity of MMP-2 and -9 in 
zymography of alendronate treated PC-3 injected in femur of SCID mice (40). 
These data suggest that the anti-bone resorptive effect of bisphosphonate in 
prostate cancer might be attributable for inhibiting MMP-2 secretion from 
prostate cancer cells by bisphosphonate, in part.  
Another important osteoclastgenic factor is parathyroid hormone related 
protein (PTHrP), which increases bone resorption and renal tubular 
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resorption of calcium in solid tumors (41). Overexpression of PTHrP in 
prostate cancer cells has been shown to induce osteolytic lesions in the bone 
of rats (42). We demonstrated that high concentration of minodronate 
inhibited protein expression of PTHrP in PC-3 and this is the first report. 
PTHrP production by primary prostatic tumors is associated with increased 
tumor size and rate of growth in an animal model, suggesting that PTHrP 
acts in an autocrine or intracrine mechanism to promote tumor growth (43). 
These findings suggest that minodronate might prevent osteoclastgenesis 
and growth of prostatic cancer cells in bone microenviroment by inhibiting 
paracrine and autocrine secretion of PTHrP from cancer cells.  
In the present study, we demonstrated that bisphosphonate treatment could 
regulate expression of some osteoclastgenic proteins such as RANKL, 
MMPs, or PTHrP as well as apoptosis related proteins in prostatic cancer 
cell lines in vitro. However, the mechanism for the regulation of the 
expression of those osteoclastogenic factors by bisphosphonate is still 
unclear. In study of: lovastatin which inhibits the synthesis of cholesterol 
and affects posttranslational modification or isoprenylation of several 
proteins including Ras in the signal transduction pathway, western blotingt 
showed lovastatin-induced decrement of MMP-9 expression as well as 
membrane localization of Ras proteins in fibroblast (44)..In another study of 
fibroblast, Aklilu et al. reported that inhibition of Ras decreased mRNA and 
protein expression of PTHrP (45). These results by others raises the 
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possibility that the inhibitory effect of bisphosphonate on isoprenylation of 
small GTP-binding protein such as Rac, Ras, Rho throught mavalonate 
pathway might link to decreased production of some kinds of growth factors 
or cytokines in cancer cells. However, in our study, mRNA and protein 
expression of MMP-2 and RANKL was decreased while the mRNA 
expression of PTHrP was not alterd in spite of decreased protein expression 
of PTHrP. In addition, OPG expression was stable with bisphosphonate 
treatment. These results imply that molecular action of bisphosphonate on 
the protein regulation in cancer cells involves multiple signaling pathways 
other than mevalonate pathway.  
In study of other cell lines, Mackie et al. demonstrated down-regulation of 
osteopontin (OPN) mRNA as well as RANKL in multiple myeloma (26). OPN 
has been shown to mediate cell attachment and migration of malignant cells. 
Moreover, Viereck et al. demonstrated that bisphosphonate treatment 
increased OPG expression from osteoblasts in vitro (46). Taken together, 
bisphosphonates might have possibilities to influence on prostatic cancer 
cells and to alter secretion of various kinds of protein in vitro. It may be 
possible that the sum activity of bisphosphonate action in the bone 
microenviroment will reflect alterations of these interactions in a dynamic 
fashion. We previously reported a case of hormone refractory prostate cancer 
with bone metastasis in which a bisphosphonate decreased not only bone pain, 
but also serum PSA levels during clinical treatment for prostate cancer (47).  
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The preclinical data including ours raises the intriguing possibility that the 
observed clinical utility of bisphosphonates in managing skeletal metastases 
may in part derive from direct inhibition of prostate cell growth and 
regulation of protein secretion from tumor cells in the bone microenviroment. 
Additional studies are required to determine if such effects of 
bisphosphonates are actually translated into the in vivo setting to 




















We have demonstrated a direct inhibitory effect of minodronate on 
proliferation of prostatic cancer cell lines. Induction of apoptosis by 
minodronate is caspase-3 dependent and activation of caspase-3 cascades 
including PARP is a main stream to cause DNA fragmentation by 
minodronate. Furthermore we have demonstrated an alteration in mRNA 
and protein expression of RANKL and MMP-2 and protein expression of 
PTHrP. Thus local decrease of such growth factor or cytokines levels in bone 
microenviroment may be an important components of the paracrine or 
autocrine mechanism by which bisphosphonate reduce bone resorption and 













FIG. 1. Effects of Minodronate on PC-3, DU145 and LN-CaP. 
 
Cells were plated at a density of 5×105 cells in 6 well plates with DMEM or 
RPMI medium containing 10% FBS and treated with treated with 0-100 μM 
of minodronate or incadronate for 72 hours (A) or 10 μM of minodonate for 
0-72 hours (B). With minodronate treatment, the number of cells was 
decreased in a time and dose dependent manner. Error bars indicate mean ± 
1 SD. Single asterisk indicates p<0.05. 
 
 
FIG.2. Detection of apoptosis. 
 
With minodronate treatment in PC-3, DNA fragmentation was detected in a 
dose dependent manner (A). Apoptotic nuclei was seen in minodronate 
treated PC-3 in TUNEL staining, magnification x200 (B).  
 
FIG. 3. Expression of bcl-2 and bax in Minodronate-treated prostate cancer 
cell lines. 
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 The expression of bcl-2 was decreased in 30 μM of minodronate but 
expression of bax was not regulated with minodronate treatment in DU145 
and PC-3 (A). Corresponding densitometric analysis of bcl-2 and bax level 
expression was shown as bcl2/bax ratio according to dose of minodronate 
(B). 
 
FIG. 4. Measurement of Caspase-3 activity.  
 
PC-3 and DU145 cells were treated for 24 hours with 0 or 30-μM 
minodronate with or without 20 μM of Z-VAD-FMK before incubating with 
caspase-3 substrate. Caspase-3 activity was increased with 30 μM of 
minodronate (A). Cytotoxic effect of minodronate was partially inhibited 
with Z-VAD-FMK treatment. Error bars indicate mean ± 1 SD.  
 
FIG. 5. Expression of PARP (Poli-ADP ribose polymerase) in 
minodronate-treated prostate cancer cell lines. 
 
The expression of full length PARP was decreased in 30 μM of minodronate 
in DU145 and PC-3. 
 
FIG. 6. Expression of proteins and cytokines in minodronate treated PC-3. 
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 PC-3 cells were treated with 0-30 μM minodronate for 24 hours prior to 
RT-PCR and western blotting or ELISA. Equal amounts of protein were 
loaded per lane for western blotting. 
(A) Expression of RANKL was assessed by PCR and western blotting.  
(B) Expression of OPG was assessed by PCR and ELISA. 
(C) Expression of MMP-2 was assessed by PCR and western blotting. 
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